RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Five Prime Therapeutics - Stock

Five Prime Therapeutics EBIT 2024

Five Prime Therapeutics EBIT

0 USD

Ticker

FPRX

ISIN

US33830X1046

WKN

A1W5T9

In 2024, Five Prime Therapeutics's EBIT was 0 USD, a 0% increase from the 0 USD EBIT recorded in the previous year.

The Five Prime Therapeutics EBIT history

YEAREBIT (undefined USD)
2024e-
2023e-
2022e-
2021e-
2020-95.61
2019-141.94
2018-146.16
2017-151.4
2016-99.21
2015286.97
2014-37.57

Five Prime Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Five Prime Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Five Prime Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Five Prime Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Five Prime Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Five Prime Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Five Prime Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Five Prime Therapeutics’s growth potential.

Five Prime Therapeutics Revenue, Profit, and EBIT History

DateFive Prime Therapeutics RevenueFive Prime Therapeutics EBITFive Prime Therapeutics Net Income
2024e9.01 M USD0 USD-93.14 M USD
2023e10.65 M USD0 USD-93.14 M USD
2022e12.56 M USD0 USD-93.14 M USD
2021e15.27 M USD0 USD-93.14 M USD
202013.18 M USD-95.61 M USD-84.33 M USD
201914.87 M USD-141.94 M USD-137.2 M USD
201849.87 M USD-146.16 M USD-140.45 M USD
201739.51 M USD-151.4 M USD-150.22 M USD
201630.69 M USD-99.21 M USD-65.7 M USD
2015379.8 M USD286.97 M USD249.65 M USD
201419.23 M USD-37.57 M USD-37.42 M USD

Five Prime Therapeutics stock margins

The Five Prime Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Five Prime Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Five Prime Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Five Prime Therapeutics's sales revenue. A higher gross margin percentage indicates that the Five Prime Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Five Prime Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Five Prime Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Five Prime Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Five Prime Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Five Prime Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Five Prime Therapeutics Margin History

Five Prime Therapeutics Gross marginFive Prime Therapeutics Profit marginFive Prime Therapeutics EBIT marginFive Prime Therapeutics Profit margin
2024e0 %0 %-1,033.87 %
2023e0 %0 %-874.28 %
2022e0 %0 %-741.76 %
2021e0 %0 %-609.97 %
20200 %-725.53 %-639.92 %
20190 %-954.27 %-922.43 %
20180 %-293.08 %-281.64 %
20170 %-383.22 %-380.23 %
20160 %-323.26 %-214.06 %
20150 %75.56 %65.73 %
20140 %-195.38 %-194.6 %

Five Prime Therapeutics Aktienanalyse

What does Five Prime Therapeutics do?

Five Prime Therapeutics Inc. is a biotech company based in South San Francisco, California. It specializes in the discovery and development of innovative therapeutics for serious diseases. The company was founded in 2001 by leading biotechnology researchers and has undergone several mergers and acquisitions. It is currently listed on the Nasdaq stock exchange under the ticker symbol "FPRX". Five Prime Therapeutics' business model is based on the discovery and development of therapeutics for diseases that have been inadequately treated. The company focuses on precision medicine approaches tailored to the individual needs of patients. Its main areas of focus include cancer therapies, inflammatory diseases, and rare genetic diseases. To achieve these goals, the company utilizes a wide range of therapeutic platforms, including antibodies, biologics, and protein therapies. These platforms are based on a deeper understanding of disease processes and mechanisms, as well as a precise understanding of biological and molecular connections in the human body. Five Prime Therapeutics also utilizes artificial intelligence and machine learning in the development of new therapeutics. The company has four main divisions: oncology, immunology, women's health, and genomics/proteomics. Each division focuses on specific indications and development programs. Some key developments and products in each division include: - Oncology: Five Prime Therapeutics has a broad pipeline of precision oncology therapeutics. One of the most important development programs is "FPA150," an antibody targeting B7-H4, a protein expressed by cancer cells. FPA150 is being tested in clinical studies for the treatment of solid tumors and cervical cancer. - Immunology: The company has also developed a pipeline of immunotherapeutics and biologics targeting the treatment of inflammatory diseases such as rheumatoid arthritis and Crohn's disease. One of the key development programs in this area is "FP-028," which targets the TGF-beta signaling pathway. - Women's Health: Five Prime Therapeutics also has a division focused on women's health. An important development program in this area is "FP-1039/GSK3052230," a biologic that could potentially be used for the treatment of ovarian cancer. - Genomics/Proteomics: As the fourth main division, the company is working on biomarker-based therapeutics targeting specific genetic mutations and signaling pathways. An important component of this work is the identification of new target molecules through genomics and proteomics technologies. Overall, Five Prime Therapeutics has achieved an impressive track record in the discovery and development of innovative therapeutics in recent years. Several of its main programs have successfully entered clinical studies and are showing promising results. Additionally, the company has established a successful partnership with GlaxoSmithKline to jointly develop new therapeutics for the treatment of cancer and inflammatory diseases. In summary, Five Prime Therapeutics is an emerging biotech company specialized in the discovery and development of innovative therapeutics for serious diseases. Through its precision medicine business model and wide range of therapeutic platforms, the company has made successful progress in the development of promising therapeutics. Five Prime Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Five Prime Therapeutics's EBIT

Five Prime Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Five Prime Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Five Prime Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Five Prime Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Five Prime Therapeutics Stock

How much did Five Prime Therapeutics achieve in EBIT for the current year?

In the current year, Five Prime Therapeutics has achieved an EBIT of 0 USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Five Prime Therapeutics.

How has the EBIT of Five Prime Therapeutics developed in recent years?

The EBIT of Five Prime Therapeutics has increased by 0% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Five Prime Therapeutics?

The EBIT of Five Prime Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Five Prime Therapeutics pay?

Over the past 12 months, Five Prime Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Five Prime Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Five Prime Therapeutics?

The current dividend yield of Five Prime Therapeutics is .

When does Five Prime Therapeutics pay dividends?

Five Prime Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Five Prime Therapeutics?

Five Prime Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Five Prime Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Five Prime Therapeutics located?

Five Prime Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Five Prime Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Five Prime Therapeutics from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.

When did Five Prime Therapeutics pay the last dividend?

The last dividend was paid out on 6/30/2024.

What was the dividend of Five Prime Therapeutics in the year 2023?

In the year 2023, Five Prime Therapeutics distributed 0 USD as dividends.

In which currency does Five Prime Therapeutics pay out the dividend?

The dividends of Five Prime Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Five Prime Therapeutics

Our stock analysis for Five Prime Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Five Prime Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.